Search clinical trials for: Placebo insulin degludec

Total 56439 results

Novo Nordisk A/S

Completed

Comparison of IDegAsp (Inclusive Three Explorative Formulations) With Insulin Degludec and Insulin Aspart Separately Injected in Subjects With Type 1 Diabetes

Diabetes | Diabetes Mellitus, Type 1

Germany
Novo Nordisk A/S

Completed

Comparison of Explorative Formulation of Insulin Degludec and Insulin Aspart Co-formulation Versus Explorative Formulation of Insulin Degludec and Insulin Aspart Separately Compared With Biphasic Insulin Aspart 30 in Male Subjects With Diabetes

Diabetes Mellitus, Type 2 | Diabetes | Diabetes Mellitus, Type 1

Germany
Novo Nordisk A/S

Completed

Safety, Pharmacokinetics and Pharmacodynamics of Two IDegAsp (One Explorative) Preparations and Two Insulin Degludec (One Explorative) Preparations in Japanese Subjects

Healthy | Diabetes

Japan
Novo Nordisk A/S

Completed

A Trial Investigating the Pharmacodynamic and Pharmacokinetic Properties of Insulin Degludec/Insulin Aspart 15 in Subjects With Type 1 Diabetes

Diabetes | Diabetes Mellitus, Type 1

Austria
Novo Nordisk A/S

Completed

A Research Study to Compare Two Types of Insulin, a New Insulin, Insulin Icodec and an Available Insulin, Insulin Degludec, in People With Type 2 Diabetes Who Have Not Used Insulin Before (ONWARDS 3) (ONWARDS 3)

Diabetes Mellitus, Type 2

United States, Mexico, Puerto Rico, Canada, Denmark, France, Austria, Taiwan, Czechia, Brazil, China, Argentina
Novo Nordisk A/S

Completed

Comparing Efficacy and Safety of Insulin Degludec/Insulin Aspart and BIAsp 30 in Subjects With Type 2 Diabetes (BOOST)

Diabetes Mellitus, Type 2 | Diabetes

China
Novo Nordisk A/S

Completed

Comparing Efficacy and Safety of Insulin Degludec/Insulin Aspart Twice Daily and Biphasic Insulin Aspart Twice Daily in Subjects With Type 2 Diabetes Mellitus Before, During and After Ramadan

Diabetes Mellitus, Type 2 | Diabetes

United Arab Emirates, Malaysia, India, South Africa, Algeria, Lebanon
Novo Nordisk A/S

Completed

Comparison of Two NN5401 Formulations Versus Biphasic Insulin Aspart 30, All in Combination With Metformin in Subjects With Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes

Poland, Spain, Germany, Finland, France
Novo Nordisk A/S

Completed

Safety, Tolerability and Pharmacokinetic and Pharmacodynamic Characteristics of Explorative Formulations of Insulin Degludec and IDegAsp 50 in Healthy Japanese Subjects

Healthy | Diabetes

Germany
Novo Nordisk A/S

Completed

A 26-week Trial Comparing Efficacy and Safety of Insulin Degludec/Insulin Aspart BID and Insulin Degludec OD Plus Insulin Aspart in Subjects With Type 2 Diabetes Mellitus Treated With Basal Insulin in Need of Treatment Intensification With Mealtime Insulin

Diabetes Mellitus, Type 2 | Diabetes

United States, France, Austria, Norway, Algeria
Novo Nordisk A/S

Completed

Comparison of the Effect of NN5401 With the Effect of NN1250 and Insulin Aspart in Subjects With Type 1 Diabetes

Diabetes | Diabetes Mellitus, Type 1

Germany
Novo Nordisk A/S

Completed

Comparison of the Effect of NN5401 With the Effect of NN1250 and Insulin Aspart in Type 1 Diabetics

Diabetes | Diabetes Mellitus, Type 1

Germany
Novo Nordisk A/S

Completed

A Randomised Trial Comparing Efficacy and Safety After Intensification With Either Insulin Aspart Once Daily as add-on or Changing to Basal Bolus Treatment With Insulin Degludec and Insulin Aspart in Subjects With Type 2 Diabetes Previously Treated With Insulin Degludec/Insulin Aspart Twice Daily (BOOST®)

Diabetes Mellitus, Type 2 | Diabetes

United States, Malaysia, Germany, Algeria, Turkey
Novo Nordisk A/S

Completed

A Pan Asian Trial Comparing Efficacy and Safety of NN5401 and Biphasic Insulin Aspart 30 in Type 2 Diabetes (BOOST™)

Diabetes Mellitus, Type 2 | Diabetes

Japan, Malaysia, Taiwan, Korea, Republic of, Hong Kong
Novo Nordisk A/S

Completed

Comparison of NN5401 With Biphasic Insulin Aspart 30 in Type 2 Diabetes (BOOST™)

Diabetes Mellitus, Type 2 | Diabetes

India, Denmark, Sweden, Malaysia, Poland, Turkey, Finland, Australia, Thailand, Taiwan
Novo Nordisk A/S

Completed

A Trial Investigating the Exposure of NN5401 in Young Adults and Elderly Subjects With Type 1 Diabetes

Diabetes | Diabetes Mellitus, Type 1

Austria
Novo Nordisk A/S

Completed

Effect of NN5401 in Japanese Subjects With Type 1 Diabetes

Diabetes | Diabetes Mellitus, Type 1

Japan
Novo Nordisk A/S

Completed

Investigation of the Response Relationship of NN5401 in Type 1 Diabetics

Diabetes | Diabetes Mellitus, Type 1

Germany
Novo Nordisk A/S

Completed

Comparison of NN5401 Versus Biphasic Insulin Aspart 30 on a Twice Daily Regimen in Subjects With Type 2 Diabetes Mellitus

Diabetes Mellitus, Type 2 | Diabetes

Japan
Novo Nordisk A/S

Completed

A Trial Investigating the Effect of NN5401 in Subjects With Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes

Germany
Sunshine Lake Pharma Co., Ltd.

Not yet recruiting

A Study of Insulin Degludec/Insulin Aspart Biosimilar (22011) Compared With Insulin Degludec/Insulin Aspart(Ryzodeg) in Participants With Type 2 Diabetes in China

Diabetes
Novo Nordisk A/S

Completed

A Trial Investigating the Pharmacodynamic Properties of NN5401 in Subjects With Type 1 Diabetes

Diabetes | Diabetes Mellitus, Type 1

Germany
Novo Nordisk A/S

Completed

Effect of Biphasic Insulin Compared to Biphasic Insulin Combined With Insulin Aspart, With or Without Metformin in Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes

Saudi Arabia, Egypt
Novo Nordisk A/S

Completed

Bioequivalence Between Two Explorative Insulin Degludec Formulations and Between Two Explorative IDegAsp Formulations in Healthy Subjects

Healthy | Diabetes

Germany
Novo Nordisk A/S

Completed

A Trial Investigating the Safety, Tolerability, Pharmacokinetics (the Exposure of the Trial Drug in the Body) and Pharmacodynamics (the Effect of the Investigated Drug on the Body) of Insulin 287 in Subjects With Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes

Germany
Novo Nordisk A/S

Completed

A Trial Investigating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Subcutaneously Administered NNC0148-0287 (Insulin 287) in Subjects With Type 2 Diabetes

Diabetes | Type 2 Diabetes Mellitus

Germany
Sunshine Lake Pharma Co., Ltd.

Completed

A Clinical Study Comparing the Pharmacokinetics and Pharmacodynamic Characteristics of Insulin Degludec Injection (RD15003) and Insulin Degludec Injection (Tresiba®) in Healthy Subjects

Type 2 Diabetes

China
Yale University

Completed

Reducing the Risk of Metabolic Decompensation in Diabetic Adolescents by Supervised School Administration of Insulin

Type 1 Diabetes Mellitus

United States
Novo Nordisk A/S

Completed

Efficacy and Safety of Faster-acting Insulin Aspart Compared to NovoRapid® Both in Combination With Insulin Degludec in Children and Adolescents With Type 1 Diabetes (onset®7)

Diabetes | Diabetes Mellitus, Type 1

Germany, United States, India, Israel, Italy, Russian Federation, Japan, Finland, Serbia, Turkey, Bulgaria, Estonia, Czechia, Lithuania, Ukraine, Poland, Latvia, Puerto Rico
Novo Nordisk A/S

Completed

Comparison of Two Biphasic Insulin Aspart Treatments in Subjects With Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes

Denmark
Novo Nordisk A/S

Completed

Comparison of NN5401 Plus Insulin Aspart With Insulin Detemir Plus Insulin Aspart in Type 1 Diabetes (BOOST™)

Diabetes | Diabetes Mellitus, Type 1

United States, Poland, Puerto Rico, Russian Federation, United Kingdom, Denmark, France, Israel, Australia, Romania
Novo Nordisk A/S

Completed

Research Study to Compare a New Medicine "Fast-acting Insulin Aspart" to Another Medicine "Insulin Aspart" in Chinese People With Diabetes

Diabetes Mellitus, Type 2 | Diabetes Mellitus, Type 1

China
Novo Nordisk A/S

Completed

Comparison of the Efficacy and Safety of Two Different Dose Adjustment Regimens for Insulin Degludec/Insulin Aspart in Subjects With Type 2 Diabetes Mellitus Previously Treated With Insulin Glargine (BOOST®)

Diabetes Mellitus, Type 2 | Diabetes

United States, Malaysia, Germany, Algeria, Turkey
Novo Nordisk A/S

Completed

Efficacy and Safety of Faster-acting Insulin Aspart Compared to NovoRapid® Both in Combination With Insulin Degludec in Adults With Type 1 Diabetes (onset®8)

Diabetes | Diabetes Mellitus, Type 1

United States, India, Israel, Italy, Japan, Russian Federation, Canada, Austria, Taiwan, Serbia, Germany, Bulgaria, Puerto Rico
Novo Nordisk A/S

Completed

A Trial Investigating the Efficacy and Safety of Insulin Degludec/Insulin Aspart Once Daily Plus Insulin Aspart for the Remaining Meals Versus Insulin Detemir Once or Twice Daily Plus Meal Time Insulin Aspart in Children and Adolescents With Type 1 Diabetes Mellitus

Diabetes | Diabetes Mellitus, Type 1

United States, India, Russian Federation, Belgium, Spain, Israel, Croatia, Serbia, North Macedonia, South Africa, Slovenia, Brazil, Poland, Canada, Czechia
Eli Lilly and Company

Recruiting

A Study to Investigate the Safety and Tolerability of LY3938577 in Healthy Participants and Participants With Type 2 Diabetes Mellitus

Healthy | Type 2 Diabetes Mellitus

United States
Novo Nordisk A/S

Completed

A Trial Assessing Changes in Blood Sugar and the Number of Periods Where Supplementation of Carbohydrate is Needed to Treat Low Blood Sugar, During Two Different Treatment Regimens of NN1250 in Type 1 Diabetics

Diabetes | Diabetes Mellitus, Type 1

Germany
Novo Nordisk A/S

Completed

Efficacy and Safety of Insulin Detemir in Combination With Insulin Aspart and Biphasic Insulin Aspart 30 in Type 2 Diabetes (PreFER)

Diabetes Mellitus, Type 2 | Diabetes

Austria, Germany, Switzerland
Novo Nordisk A/S

Completed

Comparison of Two Formulations of Biphasic Insulin Aspart 70

Healthy | Diabetes

United Kingdom
University of Colorado, Denver

Completed

Insulin Pump to Multiple Daily Injection Transition Clinical Trial (TRANSITION)

Type 1 Diabetes

United States
Novo Nordisk A/S

Completed

A 38 Week Trial Comparing Effect and Safety of Insulin Degludec/Insulin Aspart vs. Insulin Glargine Plus Insulin Aspart in Subjects With Type 2 Diabetes Treated With Basal Insulin With or Without Oral Antidiabetic Treatment in Need of Treatment Intensification

Diabetes Mellitus, Type 2 | Diabetes

United States, India, Russian Federation, Serbia, Turkey, Algeria, Czechia
Novo Nordisk A/S

Completed

Pharmacokinetics of Biphasic Insulin Aspart 50 and 70 in Japanese Healthy Volunteers

Healthy | Diabetes

Japan
Novo Nordisk A/S

Completed

Research Study Comparing a New Medicine "Fast-acting Insulin Aspart" to Another Already Available Medicine "NovoRapid"/"NovoLog" in People With Type 2 Diabetes (onset 9)

Diabetes Mellitus, Type 2 | Diabetes

United States, Poland, Croatia, Italy, Russian Federation, Spain, Canada, Serbia, Slovakia, Germany, Greece, Korea, Republic of, Czechia, Puerto Rico, Bulgaria, Romania, Argentina, Ukraine
Diasome Pharmaceuticals

Completed

Comparison of Different Insulin Dosing Algorithms Using Hepatic Directed Vesicle-Insulin Lispro and Insulin Degludec

Diabetes Mellitus, Type 1

United States
University of Washington

Completed

Comparison of Glargine to Degludec Insulin Transition With or Without a Bridging Glargine Dose (GLIDING)

Type 1 Diabetes

United States
Eli Lilly and Company

Completed

A Study of LY3374849 in Healthy Participants

Healthy

Singapore
Novo Nordisk A/S

Completed

Observational Study on the Effect of NovoMix® 30, Levemir® or NovoRapid® (Alone or Combined) in Type 2 Diabetics Previously Treated With Anti-diabetic Medication (A1chieve®)

Diabetes Mellitus, Type 2 | Diabetes

Saudi Arabia, Algeria, Argentina, Bangladesh, China, Egypt, India, Indonesia, Iran, Islamic Republic of, Jordan, Korea, Republic of, Libyan Arab Jamahiriya, Malaysia, Mexico, Morocco, Pakistan, Philippines, Russian Federation and more
Nordsjaellands Hospital
Odense University Hospital; Zealand University Hospital; Aarhus University Hospital and other collaborators

Completed

Insulin Degludec and Symptomatic Nocturnal Hypoglycaemia (HypoDeg)

Type 1 Diabetes Mellitus | Nocturnal Hypoglycemia | Recurrent Severe Hypoglycaemia

Denmark
Beijing Hospital

Not yet recruiting

Safety and Efficacy of Insulin Degludec/Insulin Aspart in Patients With T2DM

Type 2 Diabetes Mellitus

China
Novo Nordisk A/S

Completed

Comparison of Biphasic Human Insulin 30 With Biphasic Insulin Aspart in Subjects With Diabetes

Diabetes Mellitus, Type 2 | Diabetes | Diabetes Mellitus, Type 1

United Kingdom, France, Netherlands, Belgium, Ireland

3

Subscribe